Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered. In February 2021, Kazakhstan approved the two-dose Sputnik Vvaccine.
The WTO Secretariat has published an indicative list compiling information on the critical inputs for the manufacturing, distributing and administering of COVID-19 vaccines.
The first batch of Sputnik vaccine is expected to be produced at SII’s facilities in September. The parties intend to produce over 300 million doses of the vaccine in India per year.
Aikening™ is a new fusion inhibitor. It is the first and only long-acting injectable (as IV infusion QW) available as a dual therapy for treatment-experienced patients with HIV-1 replication.
Sputnik V pioneered the vaccine cocktail approach with two shots. The tests conducted by the Gamaleya Center have demonstrated validity of this approach.
In total, up to 380 million doses of CoronaVac® will be available to both self-financing participants of the Facility as well as those supported by the Gavi COVAX AMC.